Dacarbazine

Generic Name
Dacarbazine
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C6H10N6O
CAS Number
4342-03-4
Unique Ingredient Identifier
7GR28W0FJI
Background

An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.

Indication

For the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents.

Associated Conditions
Advanced Pancreatic Neuroendocrine Tumors (pNET), Advanced Soft Tissue Sarcoma, Hodgkin's Lymphoma, Metastatic Melanoma, Pheochromocytoma, Advanced Medullary thyroid cancer
Associated Therapies
-
Clinical Trials
Related News

A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine

Phase 3
Completed
Conditions
Melanoma
Interventions
Drug: Ipilimumab
Drug: Dacarbazine
First Posted Date
2015-09-09
Last Posted Date
2020-05-19
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
182
Registration Number
NCT02545075
Locations
🇨🇳

Local Institution, Shanghai, China

Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma

First Posted Date
2015-07-22
Last Posted Date
2020-08-24
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
34
Registration Number
NCT02505269
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.

First Posted Date
2014-11-18
Last Posted Date
2022-08-19
Lead Sponsor
The Lymphoma Academic Research Organisation
Target Recruit Count
170
Registration Number
NCT02292979
Locations
🇳🇱

Reinier De Graaf Gasthuis, Delft, Netherlands

🇩🇰

Rigshospitalet, Copenhagen, Denmark

🇫🇷

CHU de Clermont-Ferrand, Clermont-Ferrand, France

and more 62 locations

Comparison of Melatonin or Metformin and Dacarbazine Combination Versus Dacarbazine Alone in Disseminated Melanoma

Phase 2
Terminated
Conditions
Melanoma
Interventions
Drug: Metformin
Drug: Melatonin
Drug: Dacarbazine
First Posted Date
2014-07-15
Last Posted Date
2019-11-25
Lead Sponsor
N.N. Petrov National Medical Research Center of Oncology
Target Recruit Count
57
Registration Number
NCT02190838
Locations
🇷🇺

N.N. Petrov Research Institute of Oncology Ambulatory Chemotherapy Department, St. Petersburg, Russian Federation

🇷🇺

N.N. Petrov Research Institute of Oncology Chemotherapy and Innovative Technologies Department, St. Petersburg, Russian Federation

🇷🇺

N.N. Petrov Research Institute of Oncology Clinical Diagnostic Department, St.Petersburg, Russian Federation

Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

First Posted Date
2014-07-04
Last Posted Date
2023-11-28
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
294
Registration Number
NCT02181738
Locations
🇺🇸

Local Institution - 0025, Boston, Massachusetts, United States

🇮🇹

Local Institution - 0019, Bologna, Italy

🇬🇧

Local Institution - 0026, Oxford, Oxfordshire, United Kingdom

and more 35 locations

A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma

First Posted Date
2014-03-03
Last Posted Date
2022-04-14
Lead Sponsor
Philogen S.p.A.
Target Recruit Count
96
Registration Number
NCT02076646
Locations
🇩🇪

University Hospital, Tuebingen, Germany

🇮🇹

Azienda Ospedaliera Universitaria Senese, Siena, Italy

Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)

First Posted Date
2013-11-03
Last Posted Date
2017-01-05
Lead Sponsor
AstraZeneca
Target Recruit Count
152
Registration Number
NCT01974752
Locations
🇬🇧

Research Site, Swansea, United Kingdom

Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

First Posted Date
2013-06-04
Last Posted Date
2024-07-09
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
118
Registration Number
NCT01868451
Locations
🇺🇸

Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

🇺🇸

Stanford University Medical Center, Stanford, California, United States

and more 7 locations

Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery

First Posted Date
2013-04-18
Last Posted Date
2022-08-04
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
47
Registration Number
NCT01835145
Locations
🇺🇸

University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States

🇺🇸

University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

🇺🇸

Kaiser Permanente Washington, Seattle, Washington, United States

and more 225 locations

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma

First Posted Date
2013-01-18
Last Posted Date
2024-08-09
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
41
Registration Number
NCT01771107
Locations
🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

🇺🇸

Virginia Mason Medical Center, Seattle, Washington, United States

🇺🇸

Fred Hutchinson Cancer Center, Seattle, Washington, United States

and more 25 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy